Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Novo Nordisk A/S454 enrolled

Overview

This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.

Study Type

OBSERVATIONAL

Enrollment

454

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with type 2 diabetes

Locations (1)

Novo Nordisk Investigational Site

Bratislava, Slovakia

Outcomes

Primary Outcomes

HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Fasting plasma glucose (FPG)

Post-prandial glucose (PPG)

Weight

Hypoglycaemia

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.